T. Babinchak

发表

Use of Ribotyping To Retrospectively Identify Methicillin-Resistant Staphylococcus aureus Isolates from Phase 3 Clinical Trials for Tigecycline That Are Genotypically Related to Community-Associated Isolates

J. O'Connell, P. Bradford, B. Kreiswirth, 2005, Antimicrobial Agents and Chemotherapy.

Pyogenic vertebral osteomyelitis of the posterior elements.

T. Babinchak, D. Riley, E. B. Rotheram, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

M. Beuran, A. Razbadauskas, N. Dartois, 2008, The Journal of antimicrobial chemotherapy.

In vitro activity of DNA gyrase inhibitors, singly and in combination, against Mycobacterium avium complex.

R. Fass, T. Babinchak, 1992, Diagnostic microbiology and infectious disease.

Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals.

R. Pomerantz, T. Babinchak, J. Desimone, 2003, AIDS patient care and STDs.

A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

E. Loh, T. Babinchak, A. Yellin, 2005, BMC infectious diseases.

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

E. Loh, N. Dartois, T. Babinchak, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Adominal Infections - The European Experience

J. Tellado, Arthur J. L. Cooper, N. Dartois, 2008, Journal of chemotherapy.

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.

T. File, H. Lode, R. Masterton, 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

B. Cirincione, J. Korth-Bradley, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Infectious complications of hepatic cryosurgery.

T. Babinchak, M. L. Weaver, R. Zemel, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Clinical Spectrum of Nodular Lymphangitis

Erica Heasley, T. Babinchak, R. E. Ryncarz, 2022 .

A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections.

T. Babinchak, S. Towfigh, A. Poirier, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States.

C. Hall, T. Babinchak, Jason S Richardson, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Patients treated by a thoracic surgeon with HIV. A review.

T. Babinchak, C. Renner, 1994, Chest.

Smallpox vaccine

T. Babinchak, 2017, Reactions Weekly.

The Efﬁcacy and Safety of Tigecycline for the Treatment of Complicated Intra-Abdominal Infections: Analysis of Pooled Clinical Trial Data

E. Loh, N. Dartois, T. Babinchak, 2005 .

Oral ciprofloxacin therapy for prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans.

T. Babinchak, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.

Arthur J. L. Cooper, T. Babinchak, G. Dukart, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cardiac arrhythmias associated with coadministration of azole compounds and cisapride.

T. Babinchak, N. Chan-Tompkins, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial.

R. Pedersen, N. Qvist, T. Babinchak, 2012, Surgical infections.

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

C. Kempton, D. Quon, M. Makris, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Tigecycline: an update.

G. Stein, T. Babinchak, 2013, Diagnostic microbiology and infectious disease.

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

J. Sobel, J. Cleary, D. Cohen, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Inflammatory Reactions in HIV-1Infected Persons after Initiation of Highly Active Antiretroviral Therapy

R. Pomerantz, T. Babinchak, J. Desimone, 2000, Annals of Internal Medicine.

Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.

D. Hoban, S. Hawser, S. Bouchillon, 2011, International journal of antimicrobial agents.

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

E. Loh, N. Dartois, T. Babinchak, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections

G. Rahav, R. Pedersen, T. Babinchak, 2012, BMC Infectious Diseases.

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Arthur J. L. Cooper, N. Dartois, T. Babinchak, 2008, The Journal of antimicrobial chemotherapy.

Quinolone antibacterial agents for the treatment of genitourinary tract infections

R. Fass, T. Babinchak, 1989, European Journal of Clinical Microbiology and Infectious Diseases.

Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura

S. P. Bilir, J. Munakata, T. Babinchak, 2017, Journal of medical economics.

Exposure-response analyses of tigecycline tolerability in healthy subjects.

E. Ludwig, T. Grasela, J. Passarell, 2009, Diagnostic microbiology and infectious disease.

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010.

M. Hackel, D. Hoban, S. Hawser, 2013, Diagnostic microbiology and infectious disease.

Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.

Hui Zhang, R. Pomerantz, G. Nunnari, 2001, The Journal of infectious diseases.

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections

B. Cirincione, P. Ambrose, J. Passarell, 2007, Antimicrobial Agents and Chemotherapy.

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Giuseppe Nunnari, Hui Zhang, A. Haase, 2002, The Journal of infectious diseases.

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

B. Cirincione, P. Ambrose, J. Passarell, 2007, Antimicrobial Agents and Chemotherapy.

Herpes simplex peritonitis: case report.

T. Babinchak, R. Yakulis, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin

T. Wiemken, J. Ramirez, Arthur J. L. Cooper, 2012, BMC Infectious Diseases.

Impact of Different Factors on the Probability of Clinical Response in Tigecycline-Treated Patients with Intra-Abdominal Infections

G. Drusano, J. Korth-Bradley, S. Bhavnani, 2009, Antimicrobial Agents and Chemotherapy.

Mortality and gram-negative rod bacteraemia in the intensive care unit.

T. Babinchak, D. Gardiner, S. Scholand, 2006, The Journal of hospital infection.

Methicillin-resistant Staphylococcus aureus infection epidemiology and clinical response from tigecycline soft tissue infection trials.

M. Wible, L. Puzniak, T. Babinchak, 2014, Diagnostic microbiology and infectious disease.

Clarification to the Systematic Review and Meta-Analysis Involving Tigecycline

T. Babinchak, P. Mcgovern, A. Quintana, 2011, Antimicrobial Agents and Chemotherapy.

Compact Quadruple Therapy with the Lamivudine/Zidovudine Combination Tablet Plus Abacavir and Efavirenz, Followed by the Lamivudine/Zidovudine/Abacavir Triple Nucleoside Tablet Plus Efavirenz in Treatment-Naïve HIV-Infected Adults

D. Margolis, D. Shepp, P. Ruane, 2003, HIV clinical trials.

Clarification to the systematic review and meta-analysis involving tigecycline.

T. Babinchak, Pauline McGovern, A. Quintana, 2011, Antimicrobial agents and chemotherapy.